Protected PCI Study

• ClinicalTrials.gov Identifier: NCT02831881
• Recruitment Status: Unknown
• First Posted: July 13, 2016
• Last Update Posted: July 13, 2016
• Sponsor: Abiomed Inc.
• Collaborator: Baim Institute for Clinical Research
• Information provided by (Responsible Party): Abiomed Inc.

Study Description

Brief Summary:

A Prospective, multi-center, single-arm post-approval study of the IMPELLA® 2.5 System in Non Emergent High Risk PCI patients.

Condition or disease
Heart Failure

Detailed Description:

The objective of the study is to assess the safety and efficacy of the IMPELLA® 2.5 System in subjects undergoing non-emergent high-risk percutaneous coronary intervention (PCI) post market approval. The primary endpoint will be a composite clinical endpoint of major adverse events through 90 days following the PCI procedure. The outcome will be compared to the pre specified performance goal of 53%.

Study Design

• Study Type: Observational
• Estimated Enrollment: 369 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: PROTECTED PCI STUDY: A Prospective Clinical Trial For Patients Undergoing Protected Percutaneous Coronary Intervention With IMPELLA® 2.5 System
• Study Start Date: November 2015
• Estimated Primary Completion Date: November 2020

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. A composite rate of the following intra-procedural and post-procedural major adverse events (MAE) at 90 days post index procedure. [ Time Frame: 90 days post index procedure ]
   The primary endpoint is defined as a composite rate of the major adverse events at 90 days post index procedure

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 90 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of high risk subjects indicated for nonemergent percutaneous treatment after heart team evaluation including a cardiac surgeon of at least one de novo or restenotic lesion in a native coronary vessel or bypass graft.

Criteria

Inclusion Criteria:

1. Signed Informed Consent
2. Subject is indicated for a NON emergent percutaneous treatment of at least one de novo or restenotic lesion in a native coronary vessel or bypass graft per the judgement of a heart team including a surgeon
3. Age eligible (18 ≤ Age ≤ 90)

4. Subject presents with:

   1. Ejection Fraction≤ 35% AND at least one of the following criteria:

      Intervention on the last patent coronary conduit, or Intervention on an unprotected left main coronary artery Or

   2. Ejection Fraction ≤ 30% and intervention in patient presenting with triple vessel disease. *three-vessel or triple vessel disease is defined as at least one significant stenosis* in all three major epicardial territories: Left Anterior Descending (LAD) Artery and/or side branch, left circumflex (LCX) artery and/or side branch, Right Coronary Artery (RCA) and or side branch. *Significant stenosis is defined as at least 50% diameter stenosis by visual estimate or any total occlusion. In the case of left coronary artery dominance, a lesion in the LAD and the proximal LCX qualifies as three-vessel disease.

Exclusion Criteria:

• 1. ST Myocardial Infarction within 24 hours or CK-MB that have not normalized

  2. Pre-procedure cardiac arrest within 24 hours of enrolment requiring CPR

  3. Subject is inotrope dependent or in cardiogenic shock defined as: Hypotension (systolic BP < 90 mmHg for > 30 minutes or the need for supportive measures to maintain a systolic BP of greater than or equal to 90 mmHg) AND end organ hypoperfusion (cool extremities OR a urine output of < 30 ml/hour)

  4. Mural thrombus in the left ventricle

  5. Patient scheduled for revascularization of a total chronic occlusion (CTO) or transcatheter aortic valve replacement within 1 year of index procedure.

  6. The presence of a mechanical aortic valve or heart constrictive device

  7. Documented presence of aortic stenosis (aortic stenosis graded as ≥ +2 equivalent to an orifice area of 1.5cm2 or less.

  8. Documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥ +2)

  9. Severe peripheral arterial obstructive disease that would preclude the IMPELLA System device placement

  10. Abnormalities of the aorta that would preclude surgery, including aneurysms and extreme tortuosity or calcifications

  11. Subject with renal failure (creatinine ≥ 4mg/dL or on dialysis)

  12. Subject has history of debilitating liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3x ULN or INR (Internationalized Normalized Ratio) ≥ 2

  13. Subject has uncorrectable abnormal coagulation parameters (defined as platelet count ≤75,000/mm3 or INR ≥2.0.)

  14. History of recent (within 1 month) stroke or TIA

  15. Allergy or intolerance to heparin, aspirin, ADP receptor inhibitors(clopidogrel and ticlid) or contrast media

  16. Subject with documented heparin induced thrombocytopenia

  17. Participation in the active follow-up phase of another clinical study of an investigational drug or device

Contacts and Locations

Contacts

Contact: Ioana Ghiu, MD; ighiu@abiomed.com

Locations

United States, Michigan

Henry Ford Hospital; Recruiting

Detroit, Michigan, United States, 48202

Sponsors and Collaborators

Abiomed Inc.

Baim Institute for Clinical Research

Investigators

• Principal Investigator: William O'Neill, MD; Henry Ford Hospital

More Information

• Responsible Party: Abiomed Inc.
• ClinicalTrials.gov Identifier: NCT02831881
• Other Study ID Numbers: PROTECT III
• First Posted: July 13, 2016
• Last Update Posted: July 13, 2016
• Last Verified: July 2016

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

Additional relevant MeSH terms:

Heart Failure; Heart Diseases; Cardiovascular Diseases